These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1063 related articles for article (PubMed ID: 15073259)

  • 1. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
    Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
    J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake.
    Ceccarelli C; Antonangeli L; Brozzi F; Bianchi F; Tonacchera M; Santini P; Mazzeo S; Bencivelli W; Pinchera A; Vitti P
    Thyroid; 2011 Jul; 21(7):759-64. PubMed ID: 21568727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter.
    Giusti M; Cappi C; Santaniello B; Ceresola E; Augeri C; Lagasio C; Minuto F
    Minerva Endocrinol; 2006 Sep; 31(3):191-209. PubMed ID: 17213787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study.
    Fast S; Nielsen VE; Grupe P; Bonnema SJ; Hegedüs L
    J Nucl Med; 2009 May; 50(5):732-7. PubMed ID: 19403877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
    Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
    Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter.
    Nieuwlaat WA; Huysmans DA; van den Bosch HC; Sweep CG; Ross HA; Corstens FH; Hermus AR
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3121-9. PubMed ID: 12843153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter.
    Huysmans DA; Nieuwlaat WA; Erdtsieck RJ; Schellekens AP; Bus JW; Bravenboer B; Hermus AR
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3592-6. PubMed ID: 11061507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.
    Menzel C; Kranert WT; Döbert N; Diehl M; Fietz T; Hamscho N; Berner U; Grünwald F
    J Nucl Med; 2003 Jul; 44(7):1065-8. PubMed ID: 12843221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters.
    Nieuwlaat WA; Hermus AR; Sivro-Prndelj F; Corstens FH; Huysmans DA
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5330-6. PubMed ID: 11701700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
    Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioiodine therapy in non-toxic multinodular goitre. The possibility of effect-amplification with recombinant human TSH (rhTSH).
    Bonnema SJ; Nielsen VE; Hegedüs L
    Acta Oncol; 2006; 45(8):1051-8. PubMed ID: 17118838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of recombinant human TSH on the uptake of radioactive iodine ((123)I) by the thyroid gland in healthy beagles.
    Campos M; Peremans K; Duchateau L; Dobbeleir A; Vandermeulen E; van Hoek I; Paes G; Daminet S
    Domest Anim Endocrinol; 2010 Nov; 39(4):215-21. PubMed ID: 20688462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial.
    Nielsen VE; Bonnema SJ; Boel-Jørgensen H; Veje A; Hegedüs L
    J Clin Endocrinol Metab; 2005 Jan; 90(1):79-83. PubMed ID: 15494456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single, very low dose (0.03 mg) of recombinant human thyrotropin (rhTSH) effectively increases radioiodine uptake in the I-131 treatment of large nontoxic multinodular goiter.
    Mojsak MN; Abdelrazek S; Szumowski P; Rogowski F; Sykała M; Kostecki J; Kociura-Sawicka A; Jurgilewicz D; Myśliwiec J
    Nucl Med Rev Cent East Eur; 2016; 19(1):3-11. PubMed ID: 26841373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy.
    Fast S; Hegedüs L; Grupe P; Nielsen VE; Bluhme C; Bastholt L; Bonnema SJ
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3719-25. PubMed ID: 20519346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human TSH increases the efficacy of a fixed activity of radioiodine for treatment of multinodular goitre.
    Cubas ER; Paz-Filho GJ; Olandoski M; Goedert CA; Woellner LC; Carvalho GA; Graf H
    Int J Clin Pract; 2009 Apr; 63(4):583-90. PubMed ID: 18803554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters.
    Huysmans DA; Buijs WC; van de Ven MT; van den Broek WJ; Kloppenborg PW; Hermus AR; Corstens FH
    J Nucl Med; 1996 Dec; 37(12):2072-9. PubMed ID: 8970537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of recombinant human TSH in the management of large euthyroid multinodular goitre: a new therapeutic option? Pros and cons.
    Ceccarelli C; Brozzi F; Bianchi F; Santini P
    Minerva Endocrinol; 2010 Sep; 35(3):161-71. PubMed ID: 20938419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
    Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
    Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.